IARC group 2B

IARC Group 2B

The International Agency for Research on Cancer (IARC) classifies agents, mixtures, and exposures into different groups based on their carcinogenic risk to humans. IARC Group 2B is a classification used to denote agents that are "possibly carcinogenic to humans." This classification is used when there is limited evidence of carcinogenicity in humans and less than sufficient evidence in experimental animals.

Criteria for Classification

The classification into Group 2B is based on the following criteria:

• Limited evidence of carcinogenicity in humans: This means that a positive association has been observed between exposure to the agent and cancer, but other explanations for the observations (such as chance, bias, or confounding) could not be ruled out.
• Less than sufficient evidence of carcinogenicity in experimental animals: This indicates that the evidence from animal studies is not strong enough to classify the agent as a probable carcinogen (Group 2A).

Examples of Group 2B Agents

Some examples of agents classified as Group 2B include:

• Radiofrequency electromagnetic fields: These are emitted by wireless communication devices such as mobile phones.
• Lead: Exposure to lead and lead compounds has been associated with various health risks, including potential carcinogenic effects.
• Coffee: Previously classified as Group 2B, coffee has been re-evaluated and is no longer considered a possible carcinogen.

Implications of Group 2B Classification

The classification of an agent as Group 2B does not mean that it is a definite cause of cancer. Instead, it indicates that there is some evidence suggesting a potential risk, and further research is needed to clarify the relationship between the agent and cancer.

Research and Evaluation Process

The IARC Monographs program is responsible for evaluating the carcinogenic risks of various agents. The evaluation process involves:

1. Review of scientific literature: Comprehensive review of available studies on the agent. 2. Assessment of evidence: Evaluation of the quality and strength of the evidence. 3. Expert panel discussions: Involvement of international experts to discuss and reach a consensus on the classification.

Also see

• IARC Group 1
• IARC Group 2A
• IARC Group 3
• Carcinogen
• International Agency for Research on Cancer